Managed Care Interventions for Improving Outcomes in Acute Heart Failure Syndromes
This supplement to The American Journal of Managed Care provides information on the diagnosis and management of acute heart failure syndromes. Novel managed care interventions to improve the quality of care for acute heart failure syndromes and manage the financial burden of the disease are discussed.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Jeffrey D. Dunn, PharmD, MBA
Formulary and Contracts Manager
SelectHealth Plans
Salt Lake City, Utah
Gregg C. Fonarow, MD, FAHA, FACC
Professor of Cardiovascular Medicine
Associate Chief, Division of Cardiology
Geffen School of Medicine at UCLA
Los Angeles, California
Mihai Gheorghiade, MD, FACC
Professor of Medicine and Surgery
Associate Chief, Division of Cardiology
Northwestern University
Feinberg School of Medicine
Chicago, Illinois
Sadiya Sana Khan, BS
Division of Cardiology
Northwestern University
Feinberg School of Medicine
Chicago, Illinois
Ed Pezalla, MD, MPH
National Medical Director, Pharmacy Management
Aetna Pharmacy Management
Hartford, Connecticut
The faculty has reported the following:
Gregg C. Fonarow, MD, FAHA, FACC
Research grants: GlaxoSmithKline, Medtronic, National Institutes of Health, Novartis
Consultant and Honoraria: GlaxoSmithKline, Medtronic, Novartis, Pfizer, Scios
Mihai Gheorghiade, MD, FACC
Research grants: Merck, National Institutes of Health, Otsuka, Scios Inc, Sigma Tau
Consultant: Debbio Pharm, Errekappa Terapeutici, GlaxoSmithKline, Johnson & Johnson, Medtronic, Protein Design Labs, Solvay
Honoraria: Abbott, AstraZeneca, GlaxoSmithKline, Medtronic, Otsuka, Protein Design Labs, Scios Inc, Sigma Tau
Jeffrey D. Dunn, PharmD, MBA, Ed Pezalla, MD, MPH
Sadiya Sana Khan, BS
, and , report no financial interest/relationship relating to the topic of this activity.
The planners and managers reported no financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
Steve Casebeer
(Impact Education, LLC)
Alicia Rybovic
(Pharmacy Times Office of Continuing Professional
Education)
Kay Weigand
(University of Cincinnati)
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. The University of Cincinnati, Pharmacy Times, Impact Education, LLC, and Otsuka America Pharmaceutical, Inc, do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the University of Cincinnati, Pharmacy Times, Impact Education, LLC, or Otsuka America Pharmaceutical, Inc. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Signed disclosures are on file at the office of The American Journal of Managed Care, Plainsboro, New Jersey.
Physician Continuing Medical Education
Accreditation Statement
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of the University of Cincinnati and Impact Education, LLC. The University of Cincinnati is accredited by the ACCME to provide continuing medical education for physicians.
Credit Designation
The University of Cincinnati designates this educational activity for a maximum of 2.5 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit
commensurate with the extent of their participation in the activity.
Pharmacist Continuing Education
Accreditation Statement
Pharmacy Times Office of Continuing Professional Education is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing
pharmacy education. This program is approved for 2.5 contact hours (0.25 CEUs) under the ACPE universal program number of 290-999-08-011-H01-P. This
program is available for CE credit through December 31, 2009.
Otsuka America Pharmaceutical, Inc.
This supplement was supported by